Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

Chief Scientific Officer & COO

President and CEO

Chief Development Officer

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-ba...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2022-03-24	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2022-03-24	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2022-03-24	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer & COO
2022-03-24	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer & COO
2022-03-24	Premium	acquired	Premium	Premium	Premium	President and CEO
2022-03-24	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2021-06-08	Premium	acquired	Premium	Premium	Premium	-
2021-06-08	Premium	acquired	Premium	Premium	Premium	-
2021-06-08	Premium	acquired	Premium	Premium	Premium	-
2021-06-08	Premium	acquired	Premium	Premium	Premium	-
2021-06-08	Premium	acquired	Premium	Premium	Premium	-
2021-05-18	Premium	bought	Premium	Premium	Premium	-
2021-03-25	Premium	gifted	Premium	Premium	Premium	-
2021-03-25	Premium	gifted	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	Chief Development Officer
2021-03-16	Premium	bought	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	-
2021-03-16	Premium	bought	Premium	Premium	Premium	-

MRKR - Marker Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for MRKR